Journal Article10.2146/AJHP080211
Biosimilars: Illustration of scientific issues in two examples
11
TL;DR: Comparing erythropoietic agents requires the use of a consistent and valid definition of treatment response, and the need for valid and clinically relevant criteria for comparing the efficacy and safety of biosimilars and innovator products is considered.
read more
Abstract: Purpose. Scientific issues and clinical implications associated with the use of biosimilars (biopharmaceuticals that are similar to an innovator product, notwithstanding minor differences) are illustrated in two examples, botulinum neurotoxins and erythropoietic agents.
Summary. Comparison of Botox and Dysport, products that both contain botulinum toxin type A, revealed distinct differences in physicochemical characteristics, approved indications, dosing, and frequency of adverse events. Differentiating between botulinum toxin products on the basis of immunogenicity in the clinical setting would be of value in product selection, and pharmacists could play a valuable role in collecting antigenicity rate data and reporting them to the Food and Drug Administration (FDA) and the manufacturer. Various ethical and practical considerations are associated with the use of erythropoietic agents. The desire to optimize patient care and outcomes must be weighed against the likelihood of obtaining reimbursement for erythropoietic therapy, and reimbursement policies vary from one state to another. Comparing erythropoietic agents requires the use of a consistent and valid definition of treatment response. The definition of response that FDA will accept in the future when evaluating applications for approval of new biosimilar erythropoietic agents and establishing equivalence remains to be determined.
Conclusion. A variety of scientific and practical clinical issues are associated with the use of biosimilars, including product differences in physicochemical characteristics, reimbursement policies, and the need for valid and clinically relevant criteria for comparing the efficacy and safety of biosimilars and innovator products.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Biosimilars-why terminology matters.
Martina Weise,Marie-Christine Bielsky,Karen De Smet,Falk Ehmann,Niklas Ekman,Gopalan Narayanan,Hans-Karl Heim,Esa Heinonen,Kowid Ho,Robin Thorpe,Camille Vleminckx,Meenu Wadhwa,Christian Schneider +12 more
TL;DR: In an era where biopharmaceutical companies rely more and more on noncompetitive research and open collaboration to develop new models for drug development, IMI offers unique opportunities for academic groups and SMEs interested in translating results of their endeavors into innovative therapies.
215
A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines
Marion Moers-Carpi,Thomas Dirschka,Gabrielle Feller-Heppt,Said Hilton,Klaus Hoffmann,Wolfgang G. Philipp-Dormston,Anita Rütter,Kelvin Tan,Mary Ann Chapman,Antony Fulford-Smith +9 more
TL;DR: The data support the non-interchangeability of units of onabotulinumtoxinA and incobotulinupoxinA, and the absence of a fixed dose ratio in clinical practice.
33
The effect of network charge on the immobilization and release of proteins from chemically crosslinked dextran hydrogels.
TL;DR: It is concluded that incorporation of charge in a hydrogel network is suited as a tool for the immobilization of proteins and triggered release by increasing ionic strength.
29
Are biosimilars really generics
TL;DR: Biosimilars should not be brought to market using the same procedure applied to generics, and existing and future regulation should prevent inappropriate and automatic substitution of a biosimilar for a reference biopharmaceutical product.
26
Medicamentos biosimilares. Controversias científicas y legales
TL;DR: Su entrada en el mercado promovera la competencia and conseguira disminuir el alto impacto economico that soportan los sistemas sanitarios, tras the incorporacion of nuevas terapias basadas en el uso of medicamentos de biotecnologia.
13
References
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
Heinz Ludwig,Simon Van Belle,Peter Barrett-Lee,Gunnar Birgegård,Carsten Bokemeyer,Pere Gascón,Paris Kosmidis,Maciej Krzakowski,Johan W.R. Nortier,Patrizia Olmi,Maurice Schneider,Dirk Schrijvers +11 more
TL;DR: The European Cancer Anaemia Survey (ECAS) was conducted to prospectively evaluate the prevalence, incidence and treatment of anaemia in European cancer patients, including the relationship of mild, moderate and severe anaemia to performance status.
911
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
TL;DR: Extension and later removal of "functional" sprouts indicate their fundamental importance in the repair of paralyzed endplates, a finding with ramifications for the vital process of nerve regeneration.
690
Symptomatology of anemia
Heinz Ludwig,Kathrin Strasser +1 more
TL;DR: It was shown that raising hemoglobin levels with epoetin alfa ameliorated the symptoms of anemia and significantly improved the functional status and overall quality of life in cancer patients.
230
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs
TL;DR: The performance of biopharmaceuticals relies on strict production protocols and close monitoring of their activity in the clinical situation, and the issue of biogenerics is gaining more and more interest and different critical elements in the development of biOGenerics are touched upon.
209
Negative regulation of the erythropoietin gene expression by the GATA transcription factors.
TL;DR: It is concluded that the hGATA-1, 2, and 3 transcription factors specifically bind to the GATA element in the human Epo gene promoter and negatively regulateEpo gene expression.
132